MX344595B - Humanizacion rapida de anticuerpos. - Google Patents

Humanizacion rapida de anticuerpos.

Info

Publication number
MX344595B
MX344595B MX2013007659A MX2013007659A MX344595B MX 344595 B MX344595 B MX 344595B MX 2013007659 A MX2013007659 A MX 2013007659A MX 2013007659 A MX2013007659 A MX 2013007659A MX 344595 B MX344595 B MX 344595B
Authority
MX
Mexico
Prior art keywords
human framework
antibodies
encoding
framework region
humanized
Prior art date
Application number
MX2013007659A
Other languages
English (en)
Other versions
MX2013007659A (es
Inventor
Jay M Short
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of MX2013007659A publication Critical patent/MX2013007659A/es
Publication of MX344595B publication Critical patent/MX344595B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un método para la generación de anticuerpos de longitud completa humanizados en células de mamífero; una genoteca de variantes humanizadas se provee con alta diversidad de marco validada sin necesidad de retro-mutaciones para retener afinidad original; bibliotecas de fragmentos que codifican CDR sintéticas derivadas de un anticuerpo de plantilla son ligadas a la fragmentos que codifican la región de marco humanos de un acervo de marco humano limitado sólo a las secuencias de línea germinal de anticuerpos funcionalmente expresados; el vector comprende una secuencia de ácido nucleico que codifica la región de marco 4 de HC; no se requiere injerto de CDR o despliegue de fagos.
MX2013007659A 2010-12-31 2011-12-28 Humanizacion rapida de anticuerpos. MX344595B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061428917P 2010-12-31 2010-12-31
PCT/US2011/067589 WO2012092374A2 (en) 2010-12-31 2011-12-28 Express humanization of antibodies

Publications (2)

Publication Number Publication Date
MX2013007659A MX2013007659A (es) 2013-09-16
MX344595B true MX344595B (es) 2016-12-20

Family

ID=46383849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007659A MX344595B (es) 2010-12-31 2011-12-28 Humanizacion rapida de anticuerpos.

Country Status (9)

Country Link
US (4) US9683054B2 (es)
EP (3) EP2658970B1 (es)
CN (2) CN103620032B (es)
AU (4) AU2011352205B2 (es)
CA (1) CA2823044C (es)
DK (1) DK2658970T3 (es)
ES (2) ES2899186T3 (es)
MX (1) MX344595B (es)
WO (1) WO2012092374A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344595B (es) 2010-12-31 2016-12-20 Bioatla Llc Humanizacion rapida de anticuerpos.
JP6469012B2 (ja) 2012-10-22 2019-02-13 ファウンテン バイオファーマ インコーポレーテッドＦｏｕｎｔａｉｎ Ｂｉｏｐｈａｒｍａ Ｉｎｃ． インターロイキン−６に対する抗体およびその使用
EP4610368B1 (en) 2013-08-05 2026-02-04 Twist Bioscience Corporation De novo synthesized gene libraries
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
CN104833625B (zh) * 2015-06-04 2018-02-23 武汉友芝友生物制药有限公司 表达重组抗体cho细胞系稳定性的早期鉴定方法
IL258164B (en) 2015-09-18 2022-09-01 Twist Bioscience Corp Methods for modulating protein and cellular activity and method for nucleic acid synthesis
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
SG11201901563UA (en) 2016-08-22 2019-03-28 Twist Bioscience Corp De novo synthesized nucleic acid libraries
JP6871364B2 (ja) 2016-09-21 2021-05-12 ツイスト バイオサイエンス コーポレーション 核酸に基づくデータ保存
EP4556433A3 (en) 2017-02-22 2025-08-06 Twist Bioscience Corporation Nucleic acid based data storage
AU2018226857B2 (en) 2017-03-03 2025-01-02 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
JP7341900B2 (ja) 2017-03-03 2023-09-11 オブシディアン セラピューティクス， インコーポレイテッド 免疫療法のためのｃｄ１９組成物及び方法
WO2018170169A1 (en) 2017-03-15 2018-09-20 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
EP3401328A1 (en) * 2017-05-10 2018-11-14 Bayer Pharma Aktiengesellschaft One step antibody humanization by golden gate based germline framework region shuffling
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566209B (zh) 2017-06-12 2024-08-30 特韦斯特生物科学公司 无缝核酸装配方法
EP3681906A4 (en) 2017-09-11 2021-06-09 Twist Bioscience Corporation GPCR-BINDING PROTEINS AND THEIR SYNTHESIS
KR102889470B1 (ko) 2017-10-20 2025-11-21 트위스트 바이오사이언스 코포레이션 폴리뉴클레오타이드 합성을 위한 가열된 나노웰
CA3088911A1 (en) 2018-01-04 2019-07-11 Twist Bioscience Corporation Dna-based storage device and method for synthesizing polynucleotides using the device
GB201802201D0 (en) 2018-02-09 2018-03-28 Ultrahuman Five Ltd Binding agents
WO2019222706A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
KR20210019464A (ko) * 2018-06-05 2021-02-22 바이오아트라, 인코퍼레이티드 항 il-22 항체, 항체 단편, 이의 면역접합체 및 이의 용도
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
CA3124980A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CN113785057A (zh) * 2019-02-26 2021-12-10 特韦斯特生物科学公司 用于抗体优化的变异核酸文库
JP2022521551A (ja) 2019-02-26 2022-04-08 ツイスト バイオサイエンス コーポレーション Ｇｌｐ１受容体の変異体核酸ライブラリ
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
US12091777B2 (en) 2019-09-23 2024-09-17 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
BR112022011235A2 (pt) 2019-12-09 2022-12-13 Twist Bioscience Corp Bibliotecas de variantes de ácido nucleico para receptores de adenosina
PH12022553181A1 (en) 2020-05-26 2024-03-04 Boehringer Ingelheim Int Anti-pd-1 antibodies
TW202317620A (zh) 2021-06-04 2023-05-01 德商百靈佳殷格翰國際股份有限公司 抗ＳＩＲＰα抗體
US20250223376A1 (en) 2021-09-20 2025-07-10 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
EP4522757A2 (en) 2022-05-13 2025-03-19 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
JP2025528068A (ja) 2022-08-03 2025-08-26 ボイジャー セラピューティクス インコーポレイテッド 血液脳関門を通過させるための組成物及び方法
WO2025074337A1 (en) 2023-10-06 2025-04-10 Boehringer Ingelheim International Gmbh Use of anti-sirp-alpha antibodies to treat a liver disease or disorder
TW202535460A (zh) 2023-10-06 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗ＳＩＲＰ－α抗體用於治療癌症之用途
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
US20250277020A1 (en) 2024-03-01 2025-09-04 Boehringer Ingelheim International Gmbh Antibodies to connective tissue growth factor (ctgf) and uses thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
DE3588239T3 (de) 1985-03-30 2007-03-08 Kauffman, Stuart A., Santa Fe Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
FI915411A0 (fi) 1989-05-16 1991-11-15 Scripps Research Inst Samexpression av heteromeriska receptorer.
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US7381803B1 (en) * 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6537776B1 (en) * 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
UA75318C2 (en) * 1996-09-26 2006-04-17 Chugai Pharmaceutical Co Ltd Antibodies against protein being affined to parathyreoid human hormone
SK40599A3 (en) 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
CN101665536B (zh) * 1997-04-07 2013-07-03 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
EP1230269A2 (en) * 1999-11-03 2002-08-14 Maxygen, Inc. Antibody diversity generation
AU2002233340B2 (en) 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
IL166244A0 (en) * 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
EP1472373A4 (en) * 2002-01-14 2005-07-27 Diversa Corp PROCESSES FOR THE PRODUCTION AND PURIFICATION OF DOUBLE STRANDED POLYNUCLEOTIDES
WO2004050836A2 (en) * 2002-11-27 2004-06-17 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactic proteins
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
JP2009511067A (ja) 2005-10-14 2009-03-19 メディミューン，エルエルシー 抗体ライブラリーの細胞提示
AU2007223903B2 (en) * 2006-03-06 2013-09-05 Medimmune, Llc Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
PE20081456A1 (es) * 2006-10-06 2008-11-27 Takeda Pharmaceutical Anticuerpo monoclonal contra nectina 2
KR101546441B1 (ko) * 2006-12-20 2015-08-24 엠엠알글로벌, 인코포레이티드 항체 및 이들의 제조 및 사용 방법
WO2008092209A1 (en) * 2007-02-01 2008-08-07 Arana Therapeutics Limited Protein construct with improved properties
CN101720368A (zh) * 2007-03-09 2010-06-02 中国抗体制药有限公司 储备多样性最大化的功能性人化抗体文库之构建及应用
GB0710614D0 (en) * 2007-06-04 2007-07-11 Lonza Biologics Plc Mammalian expression vector with a highly efficient secretory signal sequence
US7947495B2 (en) 2007-11-01 2011-05-24 Abbott Biotherapeutics Corp. Immunoglobulin display vectors
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
AU2009313958B2 (en) 2008-11-13 2015-09-10 Femta Pharmaceuticals, Inc. Humanized anti-IL-6 antibodies
EP2356597A1 (en) * 2008-11-14 2011-08-17 Project Frog, Inc. Methods and systems for modular buildings
CN101928345B (zh) * 2010-06-21 2012-08-29 中国科学技术大学 一种人源化抗体及其人源化改造方法
MX344595B (es) * 2010-12-31 2016-12-20 Bioatla Llc Humanizacion rapida de anticuerpos.
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
MX2013007659A (es) 2013-09-16
EP2658970A4 (en) 2015-05-06
CN105602960A (zh) 2016-05-25
WO2012092374A2 (en) 2012-07-05
EP2658970A2 (en) 2013-11-06
ES2899186T3 (es) 2022-03-10
WO2012092374A3 (en) 2012-10-18
US20220325002A1 (en) 2022-10-13
EP2658970B1 (en) 2016-09-28
AU2018200318A1 (en) 2018-02-01
AU2016228196A1 (en) 2016-10-06
US20200157247A1 (en) 2020-05-21
DK2658970T3 (en) 2017-01-16
US20130303399A1 (en) 2013-11-14
CN103620032B (zh) 2016-02-24
CN105602960B (zh) 2021-03-19
EP3153583A1 (en) 2017-04-12
AU2019203048A1 (en) 2019-05-23
CA2823044C (en) 2022-08-16
WO2012092374A9 (en) 2012-11-22
AU2011352205B2 (en) 2016-06-16
EP4008781A1 (en) 2022-06-08
AU2011352205A1 (en) 2013-07-11
CA2823044A1 (en) 2012-07-05
US10562981B2 (en) 2020-02-18
EP3153583B1 (en) 2021-10-20
US11396556B2 (en) 2022-07-26
CN103620032A (zh) 2014-03-05
ES2609439T3 (es) 2017-04-20
AU2019203048B2 (en) 2020-10-22
US9683054B2 (en) 2017-06-20
US20170247473A1 (en) 2017-08-31
AU2016228196B2 (en) 2018-03-01
AU2018200318B2 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
MX344595B (es) Humanizacion rapida de anticuerpos.
MX2013001900A (es) Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
EA201490931A1 (ru) Связывающие молекулы в отношении всма и cd3
RU2014136103A (ru) Антагонистические антитела против рецептора IL-7 и способы
MX2012002427A (es) Anticuerpos anticina que se unen a quimiocinas cc multiples.
JP2015519055A5 (es)
JP2017114866A5 (es)
GB201208708D0 (en) Antibodies
IL196914A (en) Isolated monoclonal antibodies with sequences of different regions that specifically bind il-31, polynucleotide and expression vectors encoding antibodies, methods for their production and use
NZ706004A (en) Antibodies for treatment of cancer expressing claudin 6
RU2014103784A (ru) Антитело, блокирующее agr2, и его применение
TN2014000107A1 (en) Anti-aplhabetatcr antibody
JP2020504101A5 (es)
BR112016025352A2 (pt) métodos de produção de uma biblioteca de clones de células eucarióticas, método de produção de um repertório diverso de ligantes, método de triagem para uma célula de um fenótipo desejado, método de triagem para um ligante que reconhece um alvo, biblioteca, biblioteca in vitro de clones de células eucarióticas, recipiente contendo células eucarióticas, uso de uma nuclease específica de sítio, usos da biblioteca, método para converter as populações de anticorpo de cadeia simples (scfv) em imunoglobulina (ig) ou fragmento, e método que permite a reformatação de quaisquer dois elementos de dna unidos a um vetor
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
TN2011000524A1 (en) Antibodies specific to cadherin -17
NZ608318A (en) Anti-cxcl13 antibodies and methods of using the same
WO2012145469A8 (en) Human monoclonal antibodies specific for glypican-3 and use thereof
TN2017000552A1 (en) Antibody constructs for msln and cd3.
NZ607680A (en) Novel antigen binding proteins
RU2018119366A (ru) Мыши с гуманизированной легкой цепью
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
EP4477668A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2012092376A3 (en) Comprehensive monoclonal antibody generation
NZ717429A (en) Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly

Legal Events

Date Code Title Description
FG Grant or registration